Oculis Holding AG (NASDAQ:OCS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.50.

A number of research firms have issued reports on OCS. JPMorgan Chase & Co. began coverage on Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective for the company. Bank of America reduced their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. HC Wainwright lifted their price target on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Chardan Capital reissued a “buy” rating and set a $51.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of Oculis in a report on Tuesday, November 11th.

Oculis Stock Performance

Oculis stock opened at $23.84 on Friday. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $24.50. The stock’s 50 day simple moving average is $20.24 and its two-hundred day simple moving average is $19.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -9.46 and a beta of 0.31.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.23 million. As a group, analysts expect that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aventura Private Wealth LLC bought a new stake in Oculis in the fourth quarter worth $80,000. Bosun Asset Management LLC purchased a new position in shares of Oculis in the 2nd quarter worth about $378,000. Marshall Wace LLP bought a new position in Oculis in the 2nd quarter worth about $393,000. Geode Capital Management LLC grew its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.